DE102006025884A1 - Adapter with a connector for a nebulizer - Google Patents

Abstract

An adapter comprises a connection (20) for an atomizer (1) for a fluid (2), in particular a drug, as an aerosol through an atomizer nozzle (12), wherein the connection (20) has a bore (23) with a patient-side Outlet (22) is coupled, and one with the bore (23) fluidly connected inlet (25) for an attaching breathing air hose, that the Hauptzerstäubungsrichtung of the fluid (2) is aligned parallel to the flow direction of a breathing gas, wherein in the entrance ( 25) associated with a breakthrough (24) parallel to the bore (23) in the direction of the atomizer (1) extending opening (27) is inserted. The opening (27) extends into a region facing the atomizer (1) behind the atomizer nozzle (12).

Description

The The invention relates to an adapter with a connection for a atomizer for a, in particular, a drug exhibiting fluid as an aerosol an atomizer nozzle, wherein the connection over a bore is coupled with a patient-side outlet, and with a fluidically with the bore such connected input for a breathing air hose to be fastened thereto, that the main atomization direction of the fluid parallel to the flow direction a breathing gas is aligned, wherein in a the input assigned Breakthrough a running parallel to the bore in the direction of the atomizer opening is.

Serve respirators for supplying a patient with a breathing gas via at least one gas bearing Hose line. For example, in a ventilated patient with an inflammatory Lung disease, such as As asthma or COPD ("chronic obstructive pulmonary disease"), there is a need a medicine over administer the inhalative route. In these patients is one topical treatment in the lungs often beneficial to systemic Reduce side effects of the drugs. But it can too the need or a therapeutic option exist Medicines over the inhalative route in a ventilated patient for systemic To bring effect.

The WO 02/089887 A1 discloses a T-shaped adapter for releasable attachment a nebulizer in a breathing circuit, the adapter having a housing with an upper portion having a first passage therein and a lower section with one adjacent to the first passage second passage. Between the first pass and one Inner wall surface of the upper section is a spring chamber with a spring and a valve seat is at an upper edge of the upper portion shaped. The back and forth herbewegbare valve includes a valve actuator, which is displaceable is received in the second passage and an upper surface for Actuation of the spring and attached to the valve actuator Includes valve part.

in the Furthermore, WO 2004/098689 discloses a nebulizer connection device for connecting a nebuliser to a breathing tube of a ventilator, the one breathing air guiding device with a first connection device for the connection of a breathing air inbound Breathing air line includes. A second connection device is for the connection a breathing air laxative Provided breathing air line and a third connection device serves to connect a nebulizer. A closure device is arranged on the third connection device, by the Connect of the nebulizer a flow path for one of the aerosol generated by the nebuliser is closable. A closure organ will when connecting of the nebuliser opened and closed when removed. The nebulizer connection device is disadvantageous insofar as the aerosol generated by the nebulizer in a direction perpendicular to the flow direction the breathing gas extending direction introduced into the breathing gas leading hose is due to the entry angle of the aerosol into which the respiratory gas premier Hose line a significant impaction and thus a deposition the dissolved in the aerosol Active substance in the hose line with the result of a shortage of Patients with the active substance is given.

Further shows the Journal of Pharmacological and Toxicological Methods 50 (2004) 109-119, ELSEVIER, an adapter with a connector for a nebulizer, which is opposite a patient side outlet, with an input for the with it to be connected breathing air hose from the common opening with the connection and the departure go and such a flow channel is formed such that the main direction of sputtering of a drug parallel to the flow direction a breathing gas is aligned. However, this publication is not Further details on the design of the flow channel and the inner Removal of the adapter.

Finally, the reveals EP 0 521 061 B1 a dosing device for dispensing a measured amount of a liquid as a spray with droplets of a size suitable for inhalation into the lungs by dispensing the metered amount of liquid through a nebulizer comprising a chamber for receiving the metered amount of liquid, an energy store and means for delivering a includes predetermined amount of energy to the energy storage. In addition, means are provided for free delivery of the predetermined amount of energy from the energy storage on the chamber, so as to suspend the liquid therein a predetermined pressure rise from a low pressure to a higher pressure and initiate a discharge of the liquid from the chamber. A nebulizer is used to nebulize the metered amount of the pressurized fluid.

Preferred in this context are drugs which are selected from the group consisting of anticholinergics, betamimetics, steroids, phosphodiesterase IV inhibitors, LTD4 antagonists and EGFR kinase inhibitors, antiallergic drugs, derivatives of ergot alkaloids, triptans, CGRP antagonists, phosphodiesterase V inhibitors, and combinations of such agents, eg betamimetics plus anticholinergics or betamimetics plus antiallergics. In the case of combinations, at least one of the active ingredients preferably has chemically bound water. Preference is given to using anticholinergic active substances, as monoproparates or in the form of combination preparations.

Specifically, examples of the active ingredients or salts thereof are:
Anticholinergic agents used are preferably selected from the group consisting of tiotropium bromide, oxitropium bromide, flutropium bromide, ipratropium bromide, glycopyrronium salts, trospium chloride, tolterodine, 2,2-diphenylpropionic acid tropol ester methobromide, 2,2-diphenylpropionic acid cophenester methobromide, 2-fluoro-2,2-dibutyl Diphenylacetic acid-co-ester methobromide, 2-fluoro-2,2-diphenylacetic acid-tropol ester-methobromide, 3,3 ', 4,4'-tetrafluorobenzilic acid-tropol ester-methobromide, 3,3', 4,4'-tetrafluorobenzilic acid-co-ester methobromide, 4,4'-difluorobenzilic acid-tropol ester -Methobromide, 4,4'-difluorobenzilic acid copoprene methobromide, 3,3'-difluorobenzilic acid-tropol ester methobromide, 3,3'-difluorobenzilic acid copoprene methobromide, 9-hydroxy-fluorene-9-carboxylic acid-triester-methobromide, 9-fluoro-fluorene-9- carboxylic acid-tropol ester-methobromide, 9-hydroxy-fluorene-9-carboxylic acid-co-ester methobromide, 9-fluoro-fluoren-9-carboxylic acid-co-ester methobromide, 9-methyl-fluorene-9 Carboxylic Acid Sterol Esters Methobromide, 9-Methyl-fluorene-9-carboxylic Acid Copoester Methobromide, Benzyl Acid Cyclopropyl Tropinester Methobromide, 2,2-Diphenylpropionic Acid Cyclopropyl Methacrylate, 9-Hydroxy-Xanthene-9-Carboxylic Acid Cyclopropyl Methacrylate,
9-methyl-fluorene-9-carbonsäurecyclopropyltropinester methobromide,
9-methyl-xanthene-9-carbonsäurecyclopropyltropinester methobromide,
9-hydroxy-fluorene-9-carbonsäurecyclopropyltropinester methobromide,
Methyl 4,4'-difluorobenzilate cyclopropyltropine ester methobromide, 9-hydroxy-xanthene-9-carboxylic acid tropol ester-methobromide, 9-hydroxy-xanthene-9-carboxylic acid copoester methobromide, 9-methyl-xanthene-9-carboxylic acid-triester-methobromide, 9-methyl-xanthene 9-carboxylic acid copoprene methobromide, 9-ethyl-xanthene-9-carboxylic acid tropol ester, methobromide, 9-difluoromethyl-xanthene-9-carboxylic acid tropol ester methobromide and 9-hydroxymethyl-xanthene-9-carboxylic acid copoprene methobromide, optionally in the form of their racemates, enantiomers or diastereomers and optionally in the form of their salts, solvates and / or hydrates.

to Applicable betamimetics are preferably selected from the group consisting of albuterol, bambuterol, bitolterol, broxaterol, Carbuterol, Clenbuterol, Fenoterol, Formoterol, Hexoprenaline, Ibuterol, Indacaterol, Isoetharine, Isoprenaline, Levosalbutamol, Mabuterol, Meluadrine, metaproterenol; Orciprenaline, pirbuterol, procaterol, Reproterol, Rimiterol, Ritodrine, Salmeterol, Salmefamol, Soterenot, Sulphone terol, Tiaramide, Terbutaline, Tolubuterol, CHF-1035, HOKU-81, KUL-1248, 3- (4- {6- [2-Hydroxy-2- (4-hydroxy-3-hydroxymethyl-phenyl) -ethylamino] -hexyloxy} -butyl) -benzenesulfonamide, 5- [2- (5,6-diethyl-indan-2-ylamino) -1-hydroxy-ethyl] -8-hydroxy-1H-quinolin-2-one, 4-hydroxy-7- [2 - {[2 - {[3- (2-phenylethoxy) propyl] sulphonyl} ethyl] amino} ethyl] -2 (3H) -benzothiazolone, 1- (2-fluoro-4-hydroxyphenyl) -2- [4- (1-benzimidazolyl ) -2-methyl-2-butylamino] ethanol, 1- [3- (4-methoxybenzyl-amino) -4-hydroxyphenyl] -2- [4- (1-benzimidazolyl) -2-methyl-2-butylamino] ethanol, 1- [2H-5-hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl] -2- [3- (4-N, N-dimethylaminophenyl) -2-methyl-2-propylamino] ethanol , 1- [2H-5-hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl] -2- [3- (4-methoxyphenyl) -2-methyl-2-propylamino] ethanol, 1- [2H-5-hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl] -2- [3- (4-n-butyloxyphenyl) -2-methyl-2-propylamino] ethanol, 1- [2H-5-hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl] -2- {4- [3- (4-methoxyphenyl) -1,2,4-triazol-3- yl] -2-methyl-2-butylamino} ethanol, 5-hydroxy-8- (1-hydroxy-2-isopropylaminobutyl) -2H-1,4-benzoxazin-3- (4H) -one, 1- (4-amino-3-chloro-5-trifluoromethylphenyl) -2-tert-butylamino) ethanol and 1- (4-ethoxycarbonylamino-3-cyano-5-fluorophenyl) -2- (tert -butylamino) ethanol, optionally in the form of their racemates, enantiomers or diastereomers and optionally in the form of their pharmacologically acceptable Acid addition salts, Solvates and / or hydrates.

to Applying steroids are preferably selected from the group consisting of prednisolone, prednisone, butixocortepionate, RPR-106541, Flunisolide, beclomethasone, triamcinolone, budesonide, fluticasone, Mometasone, ciclesonide, rofleponide, ST-126, dexamethasone, 6α, 9α-difluoro-17α - [(2-furanylcarbonyl) oxy] -11β-hydroxy-16α-methyl-3-oxo-androsta-1,4-diene-17β carbothioic acid (S) -fluoromethylester, 6α, 9α-difluoro-11β-hydroxy-16α-methyl-3-oxo-17α-propionyloxy-1,4-diene-17β-carbothioic acid (S) - (2-oxo-tetrahydrofuran-3S-yl) ester and etiprednol-dichloroacetate (BNP-166), optionally in the form their racemates, enantiomers or diastereomers and optionally in the form of their salts and derivatives, their solvates and / or hydrates.

Applicable PDE IV inhibitors are preferably selected from the group consisting of enprofylline, theophylline, roflumilast, ariflo (cilomilast), CP-325,366, BY343, D-4396 (Sch-351591), AWD-12-281 (GW-842470 ), N- (3,5-dichloro-1-oxo-pyridin-4-yl) -4-difluorometho xy-3-cyclopropylmethoxybenzamide, NCS-613, pumafentene, (-) p - [(4aR *, 10bS *) - 9-ethoxy-1,2,3,4,4a, 10b-hexahydro-8-methoxy-2- methylbenzo [s] [1,6] naphthyridin-6-yl] -N, N-diisopropylbenzamide, (R) - (+) - 1- (4-bromobenzyl) -4 - [(3-cyclopentyloxy) -4-methoxyphenyl ] -2-pyrrolidone, 3- (cyclopentyloxy-4-methoxyphenyl) -1- (4-N '- [N-2-cyano-S-methylisothioureido] benzyl) -2-pyrrolidone, cis [4-cyano-4- (3-cyclopentyloxy-4-methoxyphenyl) cyclohexane-1-carboxylic acid], 2-carbomethoxy-4-cyano-4- (3-cyclopropylmethoxy-4-difluoromethoxyphenyl) cyclohexan-1-one, cis [4-cyano-4- (cis] 3-cyclopropylmethoxy-4-difluoromethoxyphenyl) cyclohexan-1-ol], (R) - (+) - ethyl [4- (3-cyclopentyloxy-4-methoxyphenyl) pyrrolidin-2-ylidene] acetate, (S) - (- ) -Ethyl [4- (3-cyclopentyloxy-4-methoxyphenyl) pyrrolidin-2-ylidene] acetate, CDP840, Bay-198004, D-4418, PD-168787, T-440, T-2585, Arofylline, Atizoram, V -11294A, C1-1018, CDC-801, CDC-3052, D-22888, YM-58997, Z-15370, 9-cyclopentyl-5,6-dihydro-7-ethyl-3- (2-thienyl) -9H pyrazolo [3,4-c] -1,2,4-triazolo [4,3-a] pyridine and 9-Cyclopentyl-5,6-dihydro-7-ethyl-3- (tert -butyl) -9H-pyrazolo [3,4-c] -1,2,4-triazolo [4,3-a] pyridine, optionally in the form of their racemates, enantiomers or diastereomers, and optionally in the form of their pharmacologically acceptable acid addition salts, solvates and / or hydrates.

to Applicable LTD4 antagonists are preferably selected from the group consisting of montelukast, 1 - (((R) - (3- (2- (6,7-difluoro-2-quinolinyl) ethenyl) phenyl) -3- (2- (2-hydroxy-2-propyl) phenyl) thio) methylcyclopropane-acetic acid, 1 - (((1 (R) -3 (3- (2- (2,3-Dichlorothieno [3,2-b] pyridin-5-yl) - (E) -ethenyl ) phenyl) -3- (2- (1-hydroxy-1-methylethyl) phenyl) propyl) thio) methyl) cyclopropaneacetic acid, pranlukast, Zafirlukast, [2 - [[2- (4-tert-butyl-2-thiazolyl) -5-benzofuranyl] oxymethyl] phenyl] acetic acid, MCC-847 (ZD-3523), MN-001, MEN-91507 (LM-1507), VUF-5078, VUF-K-8707 and L-733321, if necessary in the form of their racemates, enantiomers or diastereomers, optionally in the form of their pharmakolo cally acceptable acid addition salts and optionally in the form of their salts and derivatives, their solvates and / or hydrates.

Applicable EGFR kinase inhibitors are preferably selected from the group consisting of cetuximab, trastuzumab, ABX-EGF, Mab ICR-62, 4 - [(3-chloro-4-fluorophenyl) amino] -6 - {[4- (morpholin-4-yl) -1-oxo-2-buten-1-yl] amino} -7-cyclopropylmethoxy quinazoline, 4 - [(R) - (1-phenylethyl) amino] -6 - {[ 4- (morpholin-4-yl) -1-oxo-2-buten-1-yl] amino} -7-cyclopentyloxy-quinazoline, 4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- {[4 - ((R) -6-methyl-2-oxo-morpholin-4-yl) -1-oxo-2-buten-1-yl] amino} -7 - [(S) - (tetrahydrofuran-3 -yl) oxy] quinazoline, 4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- [2 - ((S) -6-methyl-2-oxo-morpholin-4-yl] - ethoxy] -7-methoxy-quinazoline, 4 - [(3-chloro-4-fluorophenyl) amino] -6 - ({4- [N- (2-methoxy-ethyl) -N-methyl-amino] -1- oxo-2-buten-1-yl} amino) -7-cyclopropylmethoxy-quinazoline, 4 - [(R) - (1-phenylethyl) amino] -6 - ({4- [N- (tetrahydropyran-4-) yl) -N-methylamino] -1-oxo-2-buten-1-yl} amino) -7-cyclopropylmethoxyquinazoline, 4 - [(3-chloro-4-fluorophenyl) amino] -6 - ({ 4- [N- (2-methoxy-ethyl) -N-methyl-amino] -1-oxo-2-buten-1-yl} amino) -7-cyc lypentyloxy-quinazoline, 4 - [(3-chloro-4-fluorophenyl) amino] -6 - {[4- (N, N-dimethylamino) -1-oxo-2-buten-1-yl] amino} -7- [(R) - (tetrahydrofuran-2-yl) methoxy] quinazoline, 4 - [(3-ethynylphenyl) amino] -6,7-bis (2-methoxyethoxy) quinazoline, 4 - [( R) - (1-phenylethyl) amino] -6- (4-hydroxy-phenyl) -7H-pyrrolo [2,3-d] pyrimidine, 3-cyano-4 - [(3-chloro-4-fluorophenyl ) amino] -6 - {[4- (N, N-dimethylamino) -1-oxo-2-buten-1-yl] amino} -7-ethoxy-quinoline, 4 - ((R) - (1-phenyl ethyl) amino] -6 - {[4 - ((R) -6-methyl-2-oxo-morpholin-4-yl) -1-oxo-2-buten-1-yl] amino} -7-methoxy quinazoline, 4 - [(3-chloro-4-fluorophenyl) amino] -6 - {[4- (morpholin-4-yl) -1-oxo-2-buten-1-yl] amino} -7- [ (tetrahydrofuran-2-yl) methoxy] quinazoline, 4 - [(3-ethynylphenyl) amino] -6 - {[4- (5,5-dimethyl-2-oxomorpholin-4-yl) -1 -oxo-2-buten-1-yl] amino} quinazoline, 4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- {2- [4- (2-oxomorpholine-4- yl) -piperidin-1-yl] -ethoxy} -7-methoxy-quinazoline, 4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- (trans-4-amino-cyclohexan-1-yloxy ) -7-methoxy-quinazoline, 4 - [(3-chloro-4-fluoro-ph enyl) -amino] -6- (trans-4-methanesulfonylamino-cyclohexan-1-yloxy) -7-methoxy-quinazoline, 4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- (tetrahydropyran-3 -yloxy) -7-methoxy-quinazoline, 4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- {1 - [(morpholin-4-yl) -carbonyl] -piperidin-4-yloxy} - 7-methoxy-quinazoline, 4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- (piperidin-3-yloxy) -7-methoxy-quinazoline, 4 - [(3-chloro-4-fluoro -phenyl) -amino] -6- [1- (2-acetylamino-ethyl) -piperidin-4-yloxy] -7-methoxy-quinazoline, 4 - [(3-chloro-4-fluoro-phenyl) -amino] -6 - (tetrahydropyran-4-yloxy) -7-ethoxy-quinazoline, 4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- {trans-4 - [(morpholin-4-yl) -carbonyl-amino] - cyclohexane-1-yloxy} -7-methoxy-quinazoline,
4 - [(3-Chloro-4-fluoro-phenyl) -amino] -6- {1 - [(piperidin-1-yl) -carbonyl] -piperidin-4-yloxy} -7-methoxy-quinazoline, 4 - [( 3-chloro-4-fluoro-phenyl) amino] -6- (cis-4- {N - [(morpholin-4-yl) carbonyl] -N-methyl-amino} -cyclohexan-1-yloxy) -7- methoxyquinazoline, 4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- (trans-4-ethanesulfonylamino-cyclohexan-1-yloxy) -7-methoxy-quinazoline, 4 - [(3-chloro 4-fluoro-phenyl) amino] -6- (1-methanesulfonyl-piperidin-4-yloxy) -7- (2-methoxy-ethoxy) -quinazoline, 4 - [(3-chloro-4-fluoro-phenyl) amino] -6- [1- (2-methoxy-acetyl) -piperidin-4-yloxy] -7- (2-methoxyethoxy) quinazoline, 4 - [(3-ethynylphenyl) amino] -6- (tetrahydropyran-4-yloxy] -7-methoxy-quinazoline, 4 - [(3-chloro-4-fluoro-phenyl-amino] -6- (cis-4- {N - [(piperi din-1-yl) carbonyl] -N-methyl-amino} -cyclohexan-1-yloxy) -7-methoxy-quinazoline, 4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- {cis 4 - [(morpholin-4-yl) carbonylamino] -cyclohexan-1-yloxy} -7-methoxy-quinazoline, 4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- {1- [ 2- (2-oxopyrrolidin-1-yl) ethyl] -piperidin-4-yloxy} -7-methoxy-quinazoline, 4 - [(3-ethynyl-phenyl) -amino] -6- (1-acetyl-piperidine-4 -yloxy) -7-methoxy-quinazoline, 4 - [(3-ethynyl-phenyl) -amino] -6- (1-methyl-piperidin-4-yloxy) -7-methoxy-quinazoline, 4 - [(3-ethynyl -phenyl) -amino] -6- (1-methanesulfonyl-piperidin-4-yloxy) -7-methoxy-quinazoline, 4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- (1-methyl- piperidin-4-yloxy) -7 (2-methoxyethoxy) quinazoline, 4 - [(3-ethynylphenyl) amino] -6- {1 - [(morpholin-4-yl) carbonyl] piperidine-4 -yloxy} -7-methoxy-quinazoline, 4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- {1 - [(N-methyl-N-2-methoxyethyl-amino) -carbonyl] -piperidine 4-yloxy} -7-methoxy-quinazoline, 4 - [(3-chloro-4-fluoro-phenyl) -amino) -6- (1-ethyl-piperidin-4-yloxy) -7-methoxy-quinazoline, 4 - [(3-chloro-4-fluoro-phenyl) amino] -6 [cis -4- (N-methanesulfonyl-N-methyl-amino) -cyclohexan-1-yloxy] -7-methoxy-quinazoline, 4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- [cis-4- (N-acetyl-N-methyl-amino) -cyclohexan-1-yloxy] -7-methoxy-quinazoline, 4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- ( trans-4-methylamino-cyclohexan-1-yloxy) -7-methoxy-quinazoline, 4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- [trans-4- (N-methanesulfonyl-N- methyl-amino) -cyclohexan-1-yloxy] -7-methoxy-quinazoline, 4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- (trans-4-dimethylamino-cyclohexan-1-yloxy) 7-methoxy-quinazoline, 4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- (trans-4- {N - [(morpholin-4-yl) -carbonyl] -N-methyl-amino } -cyclohexan-1-yloxy) -7-methoxy-quinazoline, 4- [(3-chloro-4-fluoro-phenyl) -amino] -6- [2- (2,2-dimethyl-6-oxo-morpholine] 4-yl) -ethoxy] -7 - [(S) - (tetrahydrofuran-2-yl) -methoxy] quinazoline, 4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- (1-methanesulfonyl -piperidin-4-yloxy) -7-methoxy-quinazoline, 4 - [(3-chloro-4-fluoro-phenyl) -amino] -6- (1-cyano-piperidin-4-yloxy) -7-methoxy-quinazoline , and 4 - [(3-chloro-4-fluoro-phenyl) -amino ] -6- {1 - [(2-methoxyethyl) carbonyl] piperidin-4-yloxy} -7-methoxy-quinazoline, optionally in the form of their racemates, enantiomers or diastereomers, optionally in the form of their pharmacologically acceptable acid addition salts, their solvates and / or hydrates.

By acid addition salts with pharmacologically acceptable acids for the formation of which the compounds are optionally capable, for example, salts are selected from the group consisting of hydrochloride, hydrobromide, hydroiodide, hydrosulfate, hydrophosphate, hydromethanesulfonate, hydronitrate, hydromaleate, hydroacetate, hydrobenzoate, hydrocitrate, hydrofumarate, Hydrotartrate, hydrooxalate, hydrosuccinate, hydrobenzoate and hydro-p-toluenesulfonate, preferably hydrochloride, hydrobromide, hydrosulfate, hydrophosphate, hydrofumarate and hydromethanesulfonate understood.
As antiallergic drugs: disodium cromoglycate, nedocromil.
As derivatives of ergot alkaloids: dihydroergotamine, ergotamine.

For inhalation medicines come with the o.g. Active ingredients, as well as their salts, esters and the combination of these active substances, salts and Ester.

It is the object of the invention, an adapter of the aforementioned To create kind, which with a simple structure an optimal introduction of a generated aerosol into a tube for respiration especially human patients.

According to the invention Task solved by that is the opening into one of the atomizer facing area behind the atomizer nozzle extends.

Of the As an inhaler trained atomizer is so to the adapter for a respiratory system that connects a flow channel for the breathing gas is provided, which ensures that the full Dose of the atomized Fluids, so the complete amount of the generated by the atomizer Aerosols from which respiratory gas is delivered to the patient by the respiratory gas behind the atomizer nozzle in the directed corresponding flow channel and so the spray cloud entraining. That of the atomizer generated aerosol is directly at the place of its production of passing through the adapter Breathing gas absorbed and with a low impaction in the tube supplied to the ventilated patient, since the main atomization direction of the fluid parallel to the flow direction the breathing gas passes. Accordingly, the ventilated patient with dissolved active ingredients in aerosol form supplied and an inhalative already performed with the atomizer Continuous medication may be required after connecting the patient to the ventilation system be continued or a medication or drug administration of the patient connected to the respiratory system. At the patient-side outlet can, as in the prior art known, a respiratory mask or a tracheal tube or the like be connected.

In its embodiment, the connection for the atomizer is adapted in its geometry in regions to a mouthpiece of the atomizer into which the atomizer nozzle protrudes and which has in its wall in an area remote from the inhalation opening at least one recess which is in flow communication with the opening for the respiratory gas , Thus, in a further treatment of a patient with a respiratory system of the atomizer can be used, even without the beat system is used. Preferably, the mouthpiece is provided with two opposing recesses through which the respiratory gas or air sucked in by the patient flows, for example to inhale respirable particles of the drug.

Prefers supports the connection for the atomizer on a shoulder of the atomizer from. The connection can be sealed on the example cylindrical Shoulder of the atomizer be set.

Preferably is the opening in the area of the mouthpiece designed as a groove. The groove is relatively easy to manufacture and after inserting the mouthpiece in the connection forms the groove with a corresponding wall of the mouthpiece a circumferentially closed flow channel.

Conveniently, extends the entrance for Breakthrough associated breakthrough perpendicular to the bore. The Breathing gas thus enters the breakthrough, is at the end in the formed by the groove and the corresponding wall of the mouthpiece flow channel diverted, flows through the recesses in the mouthpiece, in which a further direction diversion takes place, and takes that generated by the atomizer nozzle in the mouthpiece Aerosol through the hole with to the patient with both breathing gas as well as to supply the drug.

To a further development, at least one valve is provided which the atomizer aerodynamically separates from the breathing gas and the breathing gas from the entrance directly to leads the patient-side departure. Sonach can be the respiration of the Patients either over the atomizer or directly.

Prefers is the atomizer for the previously explained Adapter for dispensing a certain amount of, in particular a Medicaments containing fluids as aerosol by within of the mouthpiece arranged atomizer nozzle from a Pressure accumulator formed, wherein a mechanical pressure generator the metered fluid is applied in the pressure accumulator, the abrupt for atomising is to be released, and the mouthpiece at least one opening which, in the direction of atomization seen, behind the nozzle is trained. Preferably, the pressure generator comprises a holder for one the fluid receiving replaceable reservoir, an associated drive spring with a release button and a conveyor pipe, wherein an axial clamping of the drive spring, the holder with the reservoir and the conveyor pipe in a mouthpiece displaced opposite direction and fluid from the reservoir in a pressure chamber sucks and a Beaufschla tion of the release button a relaxation of the tensioned drive spring causes the delivery pipe in the direction of the mouthpiece moves while the fluid for discharge through the atomizer nozzle with pressure applied. Advantageously, the atomizer nozzle comprises a filter system for producing two juxtaposed sprays for generating a spray cloud.

It It is understood that the above and below to be explained features not only in the specified combination, but also in other combinations are usable. The scope of the invention is only through the claims Are defined.

The Invention will be described below with reference to an embodiment with reference on the associated Drawings closer explained. It shows:

1 a partial view of a longitudinal section through an adapter according to the invention and

2 a sectional view of an atomizer for use with the adapter according to 1 ,

The atomizer 1 serves to atomize a fluid 2 , in particular a highly effective drug or the like, and is designed as a portable inhaler, which operates without propellant gas. In the atomization of the fluid 2 , Preferably a liquid, an aerosol is formed, which can be inhaled by a user, not shown.

The atomizer 1 has a replaceable reservoir 3 with the fluid 2 which has a substantially cylindrical or cartridge-like construction and from below into the open atomizer 1 can be used. In the rigid reservoir 3 there is a fluid 2 receiving bag 4 , For atomization of the fluid 2 in a predetermined adjustable amount, the nebulizer comprises 1 a pressure generator 5 with a holder 6 for the container 3 , a power spring 7 with a manually releasable release button for relaxation 8th , a conveyor pipe 9 with an inserted check valve 10 , a pressure chamber 11 and a spray nozzle 12 , the mouthpiece 13 assigned.

When axially tensioning the drive spring 7 by turning a housing lower part 18 with an inner part releasably secured thereto 17 relative to one on the mouthpiece 13 molded housing upper part 16 becomes the holder 6 with the reservoir 3 and the conveyor pipe 9 moved down and fluid from the container 3 over the check valve 10 in the pressure chamber 11 of the pressure generator 5 sucked. During the subsequent sudden relaxation of the drive spring 7 by pressing the release button 8th becomes the fluid 2 in the pressure chamber 11 from the conveyor pipe 9 upwardly displacing drive spring 7 pressurized and via the atomizer nozzle 12 spent under atomization. Atomization takes place, for example, in particles in the μm or nm range, preferably in respirable particles with a size of about 5 μm, which form a cloud or a jet of an aerosol. A user may inhale the aerosol, with supply air or breathing gas via recesses 15 in the mouthpiece 13 is sucked.

To the fluid 2 being able to administer as an aerosol in connection with a respiratory system for a, in particular human, patients, is the adapter 19 provided that a connection 20 for the atomizer 1 having, wherein the connection 20 an area 21 includes, in its geometry to the mouthpiece 13 the atomizer 1 is adjusted. The connection 20 opposite is the adapter 19 a patient-sided departure 22 on top of a hole with the connector 20 is in flow communication. For coupling with a breathing tube is the adapter 19 with a one pass 24 having entrance 25 provided, wherein the cylindrical cross-section entrance 25 with the coaxial passageway 24 perpendicular to the hole 23 is aligned. The trained as a blind hole passage 24 flows into a groove 26 executed opening 27 parallel to the hole 23 runs and extends to the recesses 15 in the mouthpiece 13 extends, extending below the atomizer nozzle 12 are located.

The breathing gas passes from the breathing air hose into the opening 24 and is at the end of the groove 26 and a corresponding wall of the mouthpiece 13 diverted flow channel formed at the end of the breathing gas through the recesses 15 in the mouthpiece 13 arrives. In the mouthpiece 13 the breathing gas is below the atomizer nozzle 12 redirected in its flow direction and takes that from the atomizer nozzle 12 in the mouthpiece 13 generated aerosol through the hole 23 with to supply the patient both with breathing gas and with the drug, wherein within the mouthpiece 13 the main atomization direction of a drug is aligned parallel to the flow direction of the respiratory gas.

Claims (9)

Adapter with a connection ( 20 ) for a nebulizer ( 1 ) for a, in particular a drug exhibiting, fluid ( 2 ) as an aerosol through a spray nozzle ( 12 ), whereby the connection ( 20 ) via a bore ( 23 ) with a patient-related exit ( 22 ) and with one with the bore ( 23 ) fluidically connected input ( 25 ) for a breathing air hose to be fastened thereto, that the main atomization direction of the fluid ( 2 ) is aligned parallel to the flow direction of a breathing gas, wherein in a the input ( 25 assigned breakthrough ( 24 ) one parallel to the bore ( 23 ) in the direction of the atomizer ( 1 ) opening ( 27 ), characterized in that the opening ( 27 ) into an atomizer ( 1 ) facing area behind the atomizer nozzle ( 12 ). Adapter according to claim 1, characterized in that the connection ( 20 ) for the atomizer ( 1 ) in its geometry partially to a mouthpiece ( 13 ) of the atomizer ( 1 ) into which the atomizer nozzle ( 12 protrudes and in its wall in a region facing away from the inhalation opening at least one recess ( 15 ), which communicates with the opening ( 27 ) is in fluid communication with the breathing gas. Adapter according to claim 1 or 2, characterized in that the connection ( 20 ) for the atomizer ( 1 ) on a shoulder of the atomizer ( 1 ) is supported. Adapter according to one of claims 1 to 3, characterized in that the opening ( 27 ) in the region of the mouthpiece ( 13 ) as a groove ( 26 ) is trained. Adapter according to one of claims 1 to 4, characterized in that the input ( 25 ) breakthrough associated with the respiratory gas ( 22 ) perpendicular to the bore ( 23 ) runs. Adapter according to claim 1, characterized in that at least one valve is provided, which the atomizer ( 1 ) fluidly separates from the breathing gas and the breathing gas from the entrance ( 25 ) directly to the patient exit ( 22 ). An atomiser for an adapter according to one of claims 1 to 6, characterized in that the atomiser ( 1 ) for delivering a certain amount of, in particular a drug, fluid ( 2 ) as an aerosol through the inside of the mouthpiece ( 13 ) arranged atomizer nozzle ( 12 ) is formed from a pressure accumulator, wherein a mechanical pressure generator ( 5 ) the metered fluid ( 2 ) is applied in the pressure accumulator, which is to be released suddenly for spraying, and the mouthpiece ( 13 ) at least one recess ( 15 ), which, seen in the direction of atomization, behind the atomizer nozzle ( 12 ) is trained. An atomiser according to claim 7, characterized in that the pressure generator ( 5 ) a holder ( 6 ) for one the fluid ( 2 ) receiving exchangeable reservoir ( 3 ), an associated drive spring ( 7 ) with a release button ( 8th ) and a conveyor tube ( 9 ), wherein an axial tensioning of the drive spring ( 7 ) the holder ( 6 ) with the reservoir ( 3 ) and the delivery pipe ( 9 ) in a mouthpiece ( 13 ) displaces opposite direction as well as fluid ( 2 ) from the reservoir ( 3 ) in a pressure chamber ( 11 ) sucks and an actuation of the release button ( 8th ) a relaxation of the tensioned drive spring ( 7 ) causes the delivery pipe ( 9 ) in the direction of the mouthpiece ( 13 ) and thereby the fluid ( 2 ) for discharge through the atomizer nozzle ( 12 ) is pressurized. atomizer according to claim 7 or 8, characterized in that the atomizer nozzle is a filter system for producing two juxtaposed sprays for generating a spray cloud.